Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Promising early results for immunotherapy-antiangiogenesis combination.

× No keyword cloud information.

15 in total

1. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.

Authors: Elizabeth Allen; Arnaud Jabouille; Lee B Rivera; Inge Lodewijckx; Rindert Missiaen; Veronica Steri; Kevin Feyen; Jaime Tawney; Douglas Hanahan; Iacovos P Michael; Gabriele Bergers
Journal: Sci Transl Med Date: 2017-04-12 Impact factor: 17.956

2. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.

Authors: Dipongkor Saha; Hiroaki Wakimoto; Cole W Peters; Slawomir J Antoszczyk; Samuel D Rabkin; Robert L Martuza
Journal: Clin Cancer Res Date: 2018-03-29 Impact factor: 12.531

Review 3. Anlotinib as a molecular targeted therapy for tumors.

Authors: Yi Gao; Pengfei Liu; Ruihua Shi
Journal: Oncol Lett Date: 2020-05-28 Impact factor: 2.967

4. Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma.

Authors: Junseong Park; Chang Gon Kim; Jin-Kyoung Shim; Jong Hoon Kim; Hoyoung Lee; Jae Eun Lee; Min Hwan Kim; Keeok Haam; Inkyung Jung; Su-Hyung Park; Jong Hee Chang; Eui-Cheol Shin; Seok-Gu Kang
Journal: Oncoimmunology Date: 2018-10-16 Impact factor: 8.110

Review 5. Intertwined regulation of angiogenesis and immunity by myeloid cells.

Authors: Lee B Rivera; Gabriele Bergers
Journal: Trends Immunol Date: 2015-03-11 Impact factor: 16.687

6. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.

Authors: Wolfgang M Brueckl; Martin Reck; Achim Rittmeyer; Jens Kollmeier; Claas Wesseler; Gunther H Wiest; Petros Christopoulos; Amanda Tufman; Petra Hoffknecht; Bernhard Ulm; Fabian Reich; Joachim H Ficker; Eckart Laack
Journal: Clin Med Insights Oncol Date: 2020-08-19

Review 7. The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy.

Authors: Olivier Guipaud; Cyprien Jaillet; Karen Clément-Colmou; Agnès François; Stéphane Supiot; Fabien Milliat
Journal: Br J Radiol Date: 2018-04-20 Impact factor: 3.039

Review 8. Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.

Authors: Nicoletta Staropoli; Domenico Ciliberto; Silvia Chiellino; Francesca Caglioti; Teresa Del Giudice; Simona Gualtieri; Angela Salvino; Alessandra Strangio; Cirino Botta; Sandro Pignata; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal: Oncotarget Date: 2016-12-13

9. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.

Authors: Ayako Shiono; Kyoichi Kaira; Atsuto Mouri; Ou Yamaguchi; Kosuke Hashimoto; Takahiro Uchida; Yu Miura; Fuyumi Nishihara; Yoshitake Murayama; Kunihiko Kobayashi; Hiroshi Kagamu
Journal: Thorac Cancer Date: 2019-02-27 Impact factor: 3.500

10. Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.

Authors: Hongge Liang; Mengzhao Wang
Journal: Cancer Manag Res Date: 2019-08-15 Impact factor: 3.989